Anavex Life Sciences (AVXL) Proxy filing summary

Executive summary

• A clear strategy is underway to drive long-term value by prioritizing blarcamesine development for early Alzheimer's, Rett syndrome, and Fragile X syndrome, with significant regulatory milestones achieved in each area.

• The company is financially stable, with $118 million in non-dilutive funding to support operations into mid-to-late fiscal 2028, and is working to regain full Nasdaq compliance.

• Leadership changes include appointing Dr. Terrie Kellmeyer as interim CEO and adding two new independent director nominees to strengthen the board’s expertise.

• The board’s plan is positioned as superior to PVG’s proposals, which are criticized as lacking credible strategy, timeline, or leadership.

Voting matters and shareholder proposals

• Shareholders are asked to vote for six independent nominees with diverse expertise in life sciences, finance, and governance.

• The board urges rejection of PVG Asset Management’s slate, citing their lack of relevant experience and risk of value destruction.

• The proxy contest centers on board control, with the board emphasizing its nominees’ qualifications and the risks of electing PVG’s candidates.

Board of directors and corporate governance

• The board was refreshed with two new independent nominees, bringing deep pharma and public company experience.

• The Special Committee terminated the former CEO for conduct inconsistent with company policy and established an Executive Committee to ensure continuity.

• The board’s composition is deliberately complementary, spanning clinical, regulatory, financial, and operational expertise.